The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Has antifungal susceptibility testing come of age
Abstract
The in vitro susceptibility of an infecting organism to the antimicrobial agent selected for therapy is one of several factors that influence the likelihood that therapy for an infection will be successful. To appreciate the value of antifungal susceptibility testing, it is helpful to review the overall predictive utility of antibacterial susceptibility testing. After >30 years of study, in vitro susceptibility can be said to predict the response of bacterial infections with an accuracy that is well summarized as the "90-60 rule": infections due to susceptible isolates respond to therapy approximately 90% of the time, whereas infections due to resistant isolates respond approximately 60% of the time. On the basis of a growing body of knowledge, standardized susceptibility testing for selected organism-drug combinations (most notably, Candida species and the azole antifungal agents) has been shown to have similar predictive utility. Antifungal susceptibility testing is now increasingly and appropriately used as a routine adjunct to the treatment of fungal infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pfaller et al. [46] set forth fluconazole clinical breakpoints that met the so-called “90–60” rule, whereby treatment success is achieved for ~90% of susceptible isolates and ~60% of non-susceptible isolates.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [46]
In the citing paper
“Susceptibility testing to fluconazole using CLSI or EUCAST broth microdilution methodology produces MIC values that correlate reasonably well with the likelihood of successful treatment outcomes [46,47].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [46]
In the citing paper
“Intensive efforts to develop standardized, reproducible, and clinically relevant susceptibility testing methods for fungi have resulted in the development of the NCCLS M27-A methodology (now updated with the essentially identical M27-A2 methodology) for susceptibility testing of yeasts [27,28].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [27]
In the citing paper
“Second, the data may be used to support a change in therapy from a parenteral agent of any class to oral fluconazole.”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [27]
In the citing paper
“First, susceptibility is useful in the evaluation of the possible causes of lack of clinical response.”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [27]
In the citing paper
“susceptibility testing may be used to identify isolates that are less likely to respond to fluconazole (A-II) or amphotericin B (B-II) (table 3) [27,30].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [27]
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Weinstein, M. P., Towns, M., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Reller, L. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,225
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,143
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Dixon, T. C., Meselson, M. S., Guillemin, J. H., & Hanna, P. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411107 · Cited by 871
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationWeinstein, M. P., Murphy, J. R., Reller, L. B., & Lichtenstein, K. A. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.1.54 · Cited by 471
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citationEspinel-Ingroff, A. V. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.198-202.1998 · Cited by 357
Flagged first, then by citations
Cited by
Sorted by citations
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citationGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Self-citationHajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Metadata
- Authors
- Rex, J. H., & Pfaller, M. A.
- Affiliations
- Texas Medical Center (US)
- University of Iowa (US)
- Corresponding author
- Rex, John H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-15
- Volume
- 35
- Issue
- 8
- Pages
- 982-989
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2118836068
- Cited by
- 361
- References
- 64
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 10 · 2023: 11 · 2022: 13 · 2021: 8 · 2020: 17 · 2019: 10 · 2018: 16 · 2017: 21 · 2016: 13 · 2015: 14 · 2014: 24 · 2013: 17 · 2012: 14
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal susceptibility testing, in vitro susceptibility, predictive utility, antifungal resistance, Candida species, azole antifungals, fungal infection, treatment response
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida, Clinical Trials as Topic, Flucytosine, Humans, Microbial Sensitivity Tests, Statistics as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
